Research Article
Atrial Fibrillation is Associated with Femoropopliteal Totally Occlusive In-Stent Restenosis: A Single-Center, Retrospective, Observational Study
Table 1
Patient’s characteristics.
| | Variables | AF group (n = 61) | Sinus group (n = 302) | value |
| | Age | 76 ± 9 | 73 ± 9 | 0.01 | | Female, n (%) | 21 (34) | 100 (33) | 0.84 | | Ambulatory | 49 (80) | 256 (85) | 0.39 | | Hypertension, n (%) | 50 (82) | 233 (77) | 0.41 | | Dyslipidemia, n (%) | 19 (31) | 128 (42) | 0.002 | | Diabetes mellitus, n (%) | 26 (43) | 166 (55) | 0.08 | | Smoking, n (%) | 6 (10) | 42 (15) | 0.49 | | Critical limb ischemia, n (%) | 18 (30) | 89 (31) | 0.83 | | Prior PCI, n (%) | 23 (37) | 101 (33) | 0.52 | | Prior CABG, n (%) | 2 (3) | 6 (2) | 0.53 | | Prior MI, n (%) | 3 (5) | 10 (3) | 0.54 | | Prior CVD, n (%) | 2 (3) | 12 (4) | 0.8 | | CKD on HD, n (%) | 8 (13) | 50 (17) | 0.72 | | Medication | | Dual-antiplatelet therapy, n (%) | 31 (51) | 226 (75) | <0.001 | | Aspirin, n (%) | 39 (64) | 250 (83) | — | | Clopidgrel, n (%) | 28 (46) | 152 (51) | — | | Prasuglel, n (%) | 4 (7) | 2 (1) | — | | Ticlopidine, n (%) | 6 (10) | 33 (11) | — | | Cilostazol, n (%) | 13 (21) | 109 (36) | — | | Anticoagulation, n (%) | 38 (62) | 10 (3) | <0.001 | | Echographic findings | | Dd (mm) | 45 ± 9 | 45 ± 8 | 0.81 | | Ds (mm) | 32 ± 10 | 31 ± 8 | 0.31 | | EDV (ml) | 83 ± 36 | 86 ± 40 | 0.68 | | ESV (ml) | 47 ± 31 | 39 ± 28 | 0.41 | | Stroke volume (ml) | 43 ± 14 | 47 ± 29 | 0.14 | | Ejection fraction (%) | 55 ± 13 | 58 ± 11 | 0.16 | | Low EF (<40%) | 11 (18%) | 32 (11) | 0.11 |
|
|
AF, atrial fibrillation; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; Mi, myocardial infarction; CVD, cerebrovascular disease; CKD, chronic kidney disease; HD, hemodialysis; DOAC, direct oral anticoagulants; EDV, end-diastolic volume; ESV, end-systolic volume; EF, ejection fraction.
|
